Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James W Denham

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 17, 2016
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trialSwetha Sridharan, Allison Steigler, Nigel A Spry, et al.
International Journal of Radiation Oncology, Biology, Physics|January 30, 2009
Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancerJames W Denham, Mahesh Kumar, Paul S Gleeson, et al.
Plos One|March 4, 2014
Exacerbation of celecoxib-induced renal injury by concomitant administration of misoprostol in ratsDustin L Cooper, Derek E Murrell, Christopher M Conder, et al.
Histopathology|April 15, 2020
Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR TrialBrett Delahunt, Judith D Murray, Allison Steigler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2012
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancerJames W Denham, Chantelle Wilcox, David S Lamb, et al.
The Lancet. Oncology|November 16, 2012
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trialJames W Denham, Chantelle Wilcox, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2023
Validation of prediction models for radiation-induced late rectal bleeding: Evidence from a large pooled population of prostate cancer patientsAlessandro Cicchetti, Claudio Fiorino, Martin A Ebert, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 23, 2011
MRI-guided prostate radiation therapy planning: Investigation of dosimetric accuracy of MRI-based dose planningJonathan Lambert, Peter B Greer, Fred Menk, et al.
The Lancet. Oncology|December 24, 2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trialJames W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology|August 19, 2014
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trialJames W Denham, David Joseph, David S Lamb, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 17, 2016
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trialSwetha Sridharan, Allison Steigler, Nigel A Spry, et al.
International Journal of Radiation Oncology, Biology, Physics|January 30, 2009
Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancerJames W Denham, Mahesh Kumar, Paul S Gleeson, et al.
Plos One|March 4, 2014
Exacerbation of celecoxib-induced renal injury by concomitant administration of misoprostol in ratsDustin L Cooper, Derek E Murrell, Christopher M Conder, et al.
Histopathology|April 15, 2020
Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR TrialBrett Delahunt, Judith D Murray, Allison Steigler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2012
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancerJames W Denham, Chantelle Wilcox, David S Lamb, et al.
The Lancet. Oncology|November 16, 2012
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trialJames W Denham, Chantelle Wilcox, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2023
Validation of prediction models for radiation-induced late rectal bleeding: Evidence from a large pooled population of prostate cancer patientsAlessandro Cicchetti, Claudio Fiorino, Martin A Ebert, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 23, 2011
MRI-guided prostate radiation therapy planning: Investigation of dosimetric accuracy of MRI-based dose planningJonathan Lambert, Peter B Greer, Fred Menk, et al.
The Lancet. Oncology|December 24, 2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trialJames W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology|August 19, 2014
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trialJames W Denham, David Joseph, David S Lamb, et al.
Pageof 10